The SELECT trial (NEJM 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by approximately 20% versus placebo in non-diabetic adults with obesity and established cardiovascular disease
How Rybelsus and Levothyroxine Work in the Body Rybelsus (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycaemic control in adults with type 2 diabetes mellitus
By the end of this discussion, you will have a comprehensive understanding of who these medications are truly for and how to pursue your health goals responsibly
[5] Better health indicators: Subcutaneous fat, while less harmful than visceral fat (fat stored around organs), can still contribute to negative health outcomes when present in excessive amounts
By targeting multiple neural pathways involved in hunger and impulse control, these medications offer a comprehensive, non-surgical option for individuals seeking to manage obesity or weight-related health issues
The incidence of congestive heart failure in type 2 diabetes: an update